Tom Cohen
—
by
The Indian pharma giant comes out of inspection with eight observations in its generic manufacturing plant.
Read More
Your email address will not be published. Required fields are marked *
Comment *
Name *
Email *
Website
Save my name, email, and website in this browser for the next time I comment.
Leave a Reply